Rosario LÃ³pez-RodrÃguez

List of Publications by Year
in descending order

41	981	471509	477307
41 papers	**981** citations	**17** h-index	**29** g-index
45 all docs	**45** docs citations	**45** times ranked	**1608** citing authors

#	Article	IF	Citations
1	High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. Journal of Clinical Microbiology, 2015, 53, 219-226.	3.9	74
2	Genetic landscape of 6089 inherited retinal dystrophies affected cases in Spain and their therapeutic and extended epidemiological implications. Scientific Reports, 2021, 11, 1526.	3.3	71
3	Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacological Research, 2008, 58, 77-84.	7.1	59
4	Effects of CYP2D6 Genotype on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2010, 30, 504-511.	1.4	57
5	Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 474-485.	2.5	51
6	Evaluation of the Relationship between Sex, Polymorphisms in *CYP2C8* and *CYP2C9*, and Pharmacokinetics of Angiotensin Receptor Blockers. Drug Metabolism and Disposition, 2013, 41, 224-229.	3.3	45
7	Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 501-511.	2.5	45
8	Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Human Psychopharmacology, 2013, 28, 205-214.	1.5	43
9	Novel genes and sex differences in COVID-19 severity. Human Molecular Genetics, 2022, 31, 3789-3806.	2.9	38
10	Lithium and venlafaxine interaction: a case of serotonin syndrome. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 397-400.	1.5	37
11	Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Human Psychopharmacology, 2014, 29, 459-469.	1.5	33
12	DRD2 Taq1A Polymorphism Modulates Prolactin Secretion Induced by Atypical Antipsychotics in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2011, 31, 555-562.	1.4	32
13	Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacological Research, 2009, 59, 393-398.	7.1	27
14	Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2011, 34, 960-971.	3.7	24
15	Pharmacogenetics of quetiapine in healthy volunteers. International Clinical Psychopharmacology, 2015, 30, 82-88.	1.7	23
16	A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. Journal of Hepatology, 2012, 56, 1230-1238.	3.7	19
17	Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study. PLoS ONE, 2016, 11, e0153140.	2.5	19
18	Genetic Variants of Interferon-Stimulated Genes and IL-28B as Host Prognostic Factors of Response to Combination Treatment for Chronic Hepatitis C. Clinical Pharmacology and Therapeutics, 2011, 90, 712-721.	4.7	18

#	Article	IF	Citations
19	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Scientific Reports, 2018, 8, 7342.	3.3	18
20	Polymorphisms in <scp><i>CYP2D6</i></scp> have a Greater Effect on Variability of Risperidone Pharmacokinetics than Gender. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 124-128.	2.5	17
21	Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. World Journal of Gastroenterology, 2016, 22, 9744.	3.3	16
22	SARS-CoV-2 Mutant Spectra at Different Depth Levels Reveal an Overwhelming Abundance of Low Frequency Mutations. Pathogens, 2022, 11, 662.	2.8	16
23	ATA homozigosity in the IL-10gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. BMC Medical Genetics, 2011, 12, 81.	2.1	15
24	Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 539-545.	2.0	14
25	IL-6–based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts. Journal of Allergy and Clinical Immunology, 2021, 147, 1652-1661.e1.	2.9	14
26	Pharmacogenetic relevance of the CYP2C93 allele in a tenoxicam bioequivalence study performed on Spaniards. Pharmacological Research, 2009, 59, 62-68.	7.1	13
27	Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. PLoS ONE, 2018, 13, e0196793.	2.5	13
28	High SARS-CoV-2 viral load is associated with a worse clinical outcome of COVID-19 disease. Access Microbiology, 2021, 3, 000259.	0.5	13
29	Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link. PLoS ONE, 2013, 8, e66143.	2.5	13
30	Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. Pharmacogenomics, 2010, 11, 1619-1625.	1.3	12
31	Diversity of Killer Cell Immunoglobulin-Like Receptor (KIR) Genotypes and KIR2DL2/3 Variants in HCV Treatment Outcome. PLoS ONE, 2014, 9, e99426.	2.5	12
32	RPE65-related retinal dystrophy: Mutational and phenotypic spectrum in 45 affected patients. Experimental Eye Research, 2021, 212, 108761.	2.6	11
33	Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy. Genes and Immunity, 2013, 14, 317-324.	4.1	10
34	SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes. Microbiology Spectrum, 2022, 10, e0022122.	3.0	10
35	Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics, 2013, 14, 1203-1214.	1.3	9
36	NGS and phenotypic ontology-based approaches increase the diagnostic yield in syndromic retinal diseases. Human Genetics, 2021, 140, 1665-1678.	3.8	9

#	Article	IF	Citations
37	Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C. PLoS ONE, 2017, 12, e0180927.	2.5	8
38	Inhibition of Tyrosine Kinase Receptor Tie2 Reverts HCV-Induced Hepatic Stellate Cell Activation. PLoS ONE, 2014, 9, e106958.	2.5	6
39	Intrahepatic angiopoietinâ€2 correlates with chronic hepatitis C progression and is induced in hepatitis C virus replicon systems. Liver International, 2017, 37, 1148-1156.	3.9	4
40	Preliminary evidence of sustained expression of angiopoietinâ€2 during monocyte differentiation in chronic hepatitis C. Liver International, 2013, 33, 864-870.	3.9	3
41	Allele and Genotype Frequencies of Serotonin and Dopamine Transporter and Receptor Polymorphisms in a Norwegian Population. Genetic Testing and Molecular Biomarkers, 2011, 15, 557-563.	0.7	2